SSRIs in late pregnancy: The risk of neonatal respiratory distress and seizures

Acta Psychiatrica Scandinavica

Volumn 123, Issue 4, 2011, Pages 318-

  Koren, Gideon ^a  

^a Motherisk Program   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

DEPRESSION; GESTATIONAL AGE; HUMAN; LETTER; MATERNAL MORBIDITY; MATERNAL WELFARE; NEONATAL RESPIRATORY DISTRESS SYNDROME; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SEIZURE; THIRD TRIMESTER PREGNANCY; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, THIRD; PRENATAL EXPOSURE DELAYED EFFECTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 79952224937     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01642.x     Document Type: Letter

References (3)

1. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-1132.
2. Warburton W, Hertzmant C, Oberlander TF. A registry study on the impact of stopping third trimesterselective serotonine reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010;121:471-479.
3. Boucher N, Koren G, Beaulac-Baillargeon L. Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit 2009;31:404-409.